Search research articles
Contact Us
Filters
Showing results (231-240 of 240) with videos related to
Page
of 24
Sort By:
You have reached the last page of results.
This site can display upto 240 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 12, 2023
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
Joao V Alessi, Arielle Elkrief, Biagio Ricciuti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 25, 2022
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS<sup>G12D</sup>-mutated non-small-cell lung cancer
B Ricciuti, J V Alessi, A Elkrief, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2023
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer
Biagio Ricciuti, Arielle Elkrief, Joao Alessi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 6, 2021
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Biagio Ricciuti, Kathryn C Arbour, Jessica J Lin, et al.
Journal for Immunotherapy of Cancer
|
February 17, 2022
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
Alessio Cortellini, Biagio Ricciuti, Victor R Vaz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 11, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer
Biagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, et al.
Clinical Lung Cancer
|
February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients
Adriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 29, 2023
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
Joao V Alessi, Xinan Wang, Arielle Elkrief, et al.
JAMA Oncology
|
June 16, 2022
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
Biagio Ricciuti, Xinan Wang, Joao V Alessi, et al.
Cancer Discovery
|
April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Page
of 24
Search research articles
Search
Showing results (231-240 of 240) with videos related to
Sort By:
Page
of 24
You have reached the last page of results.
This site can display upto 240 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 12, 2023
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
Joao V Alessi, Arielle Elkrief, Biagio Ricciuti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 25, 2022
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS<sup>G12D</sup>-mutated non-small-cell lung cancer
B Ricciuti, J V Alessi, A Elkrief, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2023
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer
Biagio Ricciuti, Arielle Elkrief, Joao Alessi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 6, 2021
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Biagio Ricciuti, Kathryn C Arbour, Jessica J Lin, et al.
Journal for Immunotherapy of Cancer
|
February 17, 2022
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
Alessio Cortellini, Biagio Ricciuti, Victor R Vaz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 11, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer
Biagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, et al.
Clinical Lung Cancer
|
February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients
Adriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 29, 2023
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
Joao V Alessi, Xinan Wang, Arielle Elkrief, et al.
JAMA Oncology
|
June 16, 2022
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
Biagio Ricciuti, Xinan Wang, Joao V Alessi, et al.
Cancer Discovery
|
April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Page
of 24